{"type":"trials","record":{"id":41605,"source_id":"clinicaltrials-gov","external_id":"NCT07428798","title":"Subtenon PRP Injection for Geographic Atrophy in Dry Age-Related Macular Degeneration","brief_summary":"This study investigates the effects of subtenon autologous platelet-rich plasma (PRP) injections on retinal structure and visual function in patients with advanced dry age-related macular degeneration (AMD). PRP is derived from the patient's own blood and contains growth factors that may support cell survival and tissue repair. These factors are thought to help reduce retinal cell loss and slow disease progression. Three PRP injections were administered to the better-seeing eye at 4-week intervals, while the fellow eye served as an untreated control. Participants were followed from baseline to 10 weeks (two weeks after the third injection). The aim is to compare changes in RPE atrophy area, photoreceptor loss, and visual function between treated and untreated eyes.","overall_status":"Completed","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Marmara University Pendik Training and Research Hospital","enrollment":14,"countries":["Turkey (Türkiye)"],"start_date":"2024-07-01","completion_date":"2024-10-30","last_update_date":"2026-02-24","source_url":"https://clinicaltrials.gov/study/NCT07428798","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"GA-PRP","age_range":"60 Years","comparator":"Untreated Fellow Eye","organization":"Marmara University Pendik Training and Research Hospital","interventions":["Subtenon Autologous Platelet-Rich Plasma Injection"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in Retina Pigment Epithelium Atrophy Area (mm²) — Baseline (Week 0) to 2 weeks after the third PRP injection (We…","Retina Pigment Epithelium Atrophy Growth Rate (Square root transformed, mm/year) — Baseline (Week 0) to Week 10 (2 week…","Change in Photoreceptor Loss Area (mm²) — Baseline (Week 0) to Week 10 (2 weeks after the third PRP injection)","Photoreceptor Loss Growth Rate (Square root transformed, mm/year) — Baseline (Week 0) to Week 10 (2 weeks after the thi…","Change in Best-Corrected Visual Acuity — Baseline (Week 0) to Week 10 (2 weeks after the third PRP injection)","Change in Reading Performance — Baseline (Week 0) to Week 10 (2 weeks after the third PRP injection)","Change in Multifocal Electroretinography P1-Wave Amplitude — Baseline (Week 0) to Week 10 (2 weeks after the third PRP…","Change in Multifocal Electroretinography P1-Wave Implicit Time — Baseline (Week 0) to Week 10 (2 weeks after the third…","Change in Vision-Related Quality of Life (NEI-VFQ-25 Score) — Baseline (Week 0) to Week 10 (2 weeks after the third PRP…"],"design_description":"NON RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Geographic Atrophy","Dry Age Related Macular Degeneration","Subtenon Autologous Platelet-Rich Plasma Injection"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07428798","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-07-01 to 2024-10-30","comparator":"Untreated Fellow Eye","confidence":"structured-source","population":"ALL · 60 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.840Z","intervention":["Subtenon Autologous Platelet-Rich Plasma Injection"],"participants":14,"study_design":"NON RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in Retina Pigment Epithelium Atrophy Area (mm²) — Baseline (Week 0) to 2 weeks after the third PRP injection (We…","Retina Pigment Epithelium Atrophy Growth Rate (Square root transformed, mm/year) — Baseline (Week 0) to Week 10 (2 week…","Change in Photoreceptor Loss Area (mm²) — Baseline (Week 0) to Week 10 (2 weeks after the third PRP injection)","Photoreceptor Loss Growth Rate (Square root transformed, mm/year) — Baseline (Week 0) to Week 10 (2 weeks after the thi…","Change in Best-Corrected Visual Acuity — Baseline (Week 0) to Week 10 (2 weeks after the third PRP injection)","Change in Reading Performance — Baseline (Week 0) to Week 10 (2 weeks after the third PRP injection)","Change in Multifocal Electroretinography P1-Wave Amplitude — Baseline (Week 0) to Week 10 (2 weeks after the third PRP…","Change in Multifocal Electroretinography P1-Wave Implicit Time — Baseline (Week 0) to Week 10 (2 weeks after the third…","Change in Vision-Related Quality of Life (NEI-VFQ-25 Score) — Baseline (Week 0) to Week 10 (2 weeks after the third PRP…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41605","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}